文献速递淋巴瘤

双重HCK/BTK抑制剂KIN-8194抑制BTK抑制剂耐药套细胞淋巴瘤的生长及整合素介导的黏附

The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
PubMed 文献 · Leukemia · 2024-03-07

研究在套细胞淋巴瘤(MCL)细胞系和原代细胞中评价双重HCK/BTK抑制剂KIN-8194,其对BTK抑制剂(BTKi)敏感与耐药细胞均有生长抑制作用:在BTKi耐药细胞中经抑制HCK、下调AKT-S6信号实现,并以HCK依赖方式抑制对纤连蛋白和基质细胞的整合素介导黏附;获得性BTKi耐药细胞仍对KIN-8194敏感。

要点

  • KIN-8194对BTKi敏感和耐药的MCL细胞系及原代MCL细胞均有生长抑制作用
  • 在BTKi耐药细胞中,KIN-8194经抑制HCK下调AKT-S6信号
  • KIN-8194以HCK依赖方式抑制MCL细胞对纤连蛋白和基质细胞的整合素介导黏附

核心结论

  • KIN-8194抑制BTKi敏感MCL细胞及具有原发性或获得性BTKi耐药的MCL细胞的生长和整合素介导黏附,作者认为其是有前景的MCL新型治疗药物。

研究设计与样本

  • 在MCL细胞系和原代MCL细胞中开展的体外研究,比较对BTKi(伊布替尼和阿卡替尼)敏感与耐药的细胞。

主要发现

  • KIN-8194对MCL细胞系和原代MCL细胞有强效生长抑制作用,且不取决于细胞对BTKi(伊布替尼和阿卡替尼)是否敏感。
  • 在BTKi耐药细胞中,该生长抑制作用由抑制HCK介导,并导致AKT-S6信号受抑。
  • KIN-8194以HCK依赖方式抑制BTKi敏感和不敏感MCL细胞对纤连蛋白和基质细胞的整合素介导黏附。
  • 具有获得性BTKi耐药的MCL细胞仍保持对KIN-8194的敏感性。

临床怎么用

  • 作者认为KIN-8194是有前景的MCL新型治疗药物,原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although Bruton's tyrosine kinase (BTK) inhibitors (BTKi) have significantly improved patient prognosis, mantle cell lymphoma (MCL) is still considered incurable due to primary and acquired resistance. We have recently shown that aberrant expression of the Src-family tyrosine kinase hematopoietic cell kinase (HCK) in MCL correlates with poor prognosis, and that genetic HCK perturbation impairs growth and integrin-mediated adhesion of MCL cells. Here, we show that KIN-8194, a dual inhibitor of BTK and HCK with in vivo activity against Myd88-L265P-driven diffuse large B-cell lymphoma and Waldenström Macroglobulinemia, has a potent growth inhibitory effect in MCL cell lines and primary MCL cells, irrespective of their sensitivity to BTKi (ibrutinib and acalabrutinib). In BTKi-resistant cells this is mediated by inhibition of HCK, which results in repression of AKT-S6 signaling. In addition, KIN-8194 inhibits integrin-mediated adhesion of BTKi-sensitive and insensitive MCL cells to fibronectin and stromal cells in an HCK-dependent manner. Finally, we show that MCL cells with acquired BTKi resistance retain their sensitivity to KIN-8194. Taken together, our data demonstrate that KIN-8194 inhibits growth and integrin-mediated adhesion of BTKi-sensitive MCL cells, as well as MCL cells with primary or acquired BTKi resistance. This renders KIN-8194 a promising novel treatment for MCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lantermans HC, Ma F, Kuil A, et al. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma. Leukemia. 2024. PMID: 38454120. doi:10.1038/s41375-024-02207-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。